EA202190749A1 - Способы комбинированной терапии - Google Patents

Способы комбинированной терапии

Info

Publication number
EA202190749A1
EA202190749A1 EA202190749A EA202190749A EA202190749A1 EA 202190749 A1 EA202190749 A1 EA 202190749A1 EA 202190749 A EA202190749 A EA 202190749A EA 202190749 A EA202190749 A EA 202190749A EA 202190749 A1 EA202190749 A1 EA 202190749A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
formula
therapy methods
combined therapy
kras
Prior art date
Application number
EA202190749A
Other languages
English (en)
Inventor
Ларс Даниэль Энгстром
Рут Вэй Аранда
Питер Олсон
Джеймс Гейл Кристенсен
Джилл Халлин
Original Assignee
Мирати Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мирати Терапьютикс, Инк. filed Critical Мирати Терапьютикс, Инк.
Publication of EA202190749A1 publication Critical patent/EA202190749A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к способам комбинированной терапии для лечения раковых заболеваний, связанных с KRas G12C. В частности, настоящее изобретение относится к способам лечения рака у субъекта, нуждающегося в этом, включающим введение субъекту терапевтически эффективного количества комбинации универсального ингибитора семейства ErbB и ингибитора KRAS G12C формулы (I), формулы I-A или формулы I-B, к фармацевтическим композициям, содержащим терапевтически эффективные количества ингибиторов, к наборам, содержащим композиции, и к способам их применения.
EA202190749A 2018-09-10 2019-09-09 Способы комбинированной терапии EA202190749A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862729189P 2018-09-10 2018-09-10
PCT/US2019/050227 WO2020055756A1 (en) 2018-09-10 2019-09-09 Combination therapies

Publications (1)

Publication Number Publication Date
EA202190749A1 true EA202190749A1 (ru) 2021-07-09

Family

ID=69778045

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190749A EA202190749A1 (ru) 2018-09-10 2019-09-09 Способы комбинированной терапии

Country Status (13)

Country Link
US (1) US20220054491A1 (ru)
EP (1) EP3849538A4 (ru)
JP (1) JP2022500379A (ru)
KR (1) KR20210075981A (ru)
CN (1) CN112955137A (ru)
AU (1) AU2019340366A1 (ru)
CA (1) CA3112043A1 (ru)
EA (1) EA202190749A1 (ru)
IL (1) IL281344A (ru)
MX (1) MX2021002805A (ru)
SG (1) SG11202102377YA (ru)
WO (1) WO2020055756A1 (ru)
ZA (1) ZA202102015B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114616232A (zh) * 2019-09-06 2022-06-10 正大天晴药业集团南京顺欣制药有限公司 氮杂环庚烷并嘧啶类衍生物及其医药用途
CN112694475A (zh) * 2019-10-23 2021-04-23 苏州泽璟生物制药股份有限公司 环烷基类和杂环烷基类抑制剂及其制备方法和应用
CN116194456A (zh) * 2020-04-30 2023-05-30 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
US20230233558A1 (en) * 2020-06-25 2023-07-27 Tolremo Therapeutics Ag Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
AU2021397214A1 (en) * 2020-12-08 2023-07-06 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors
WO2022148421A1 (en) * 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
CN117460737A (zh) * 2021-07-05 2024-01-26 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2783743C (en) * 2009-12-11 2022-10-04 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP3447069B1 (en) * 2012-11-21 2020-09-23 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
CA3024523A1 (en) * 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
US10647715B2 (en) * 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
HUE061599T2 (hu) * 2017-11-15 2023-07-28 Mirati Therapeutics Inc KRas G12C inhibotorok

Also Published As

Publication number Publication date
SG11202102377YA (en) 2021-04-29
EP3849538A4 (en) 2022-06-29
EP3849538A1 (en) 2021-07-21
KR20210075981A (ko) 2021-06-23
IL281344A (en) 2021-04-29
CN112955137A (zh) 2021-06-11
CA3112043A1 (en) 2020-03-19
MX2021002805A (es) 2021-07-15
WO2020055756A1 (en) 2020-03-19
US20220054491A1 (en) 2022-02-24
ZA202102015B (en) 2023-05-31
JP2022500379A (ja) 2022-01-04
AU2019340366A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
EA202190630A1 (ru) Способы комбинированной терапии
EA202190749A1 (ru) Способы комбинированной терапии
JOP20220008A1 (ar) مثبطات parp1
CR20200518A (es) Piridozinonas como inhibidores de parp7
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201790088A1 (ru) Ингибиторы syk
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
PH12016502353A1 (en) Pharmaceutical composition
TW201613577A (en) Pharmaceutical combinations
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy